Allarity Therapeutics Q2 2025: Assets $17M, Net Loss $2.4M

TL;DR

Allarity Q2 2025: $17M assets, $7.3M liabilities, $2.4M net loss YTD. Still burning cash.

AI Summary

Allarity Therapeutics, Inc. reported its Q2 2025 financial results for the period ending June 30, 2025. The company had total assets of $17,075,338 and total liabilities of $7,302,797, resulting in total equity of $9,772,541. For the six months ended June 30, 2025, the company reported a net loss of $2,455,702.

Why It Matters

This filing provides insight into Allarity Therapeutics' financial health and operational performance during the second quarter of 2025, which is crucial for investors assessing the company's stability and future prospects.

Risk Assessment

Risk Level: medium — The company reported a net loss, indicating ongoing operational expenses exceeding revenue, which poses a financial risk.

Key Numbers

• $17.08M — Total Assets (As of June 30, 2025, indicating the company's resources.)
• $7.30M — Total Liabilities (As of June 30, 2025, representing the company's obligations.)
• $9.77M — Total Equity (As of June 30, 2025, reflecting the net worth of the company.)
• $2.46M — Net Loss (YTD) (For the six months ended June 30, 2025, showing profitability.)

Key Players & Entities

• Allarity Therapeutics, Inc. (company) — Filer of the 10-Q report
• 20250630 (date) — End of the reporting period
• $17,075,338 (dollar_amount) — Total assets as of June 30, 2025
• $7,302,797 (dollar_amount) — Total liabilities as of June 30, 2025
• $2,455,702 (dollar_amount) — Net loss for the six months ended June 30, 2025

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share ALLR The Nasdaq
• $0 — of the issuer's common stock, par value $0.0001, outstanding. Table of Contents

Filing Documents

• allr20250630_10q.htm (10-Q) — 971KB
• ex_823411.htm (EX-31.1) — 12KB
• ex_823412.htm (EX-31.2) — 12KB
• ex_823413.htm (EX-32) — 7KB
• 0001437749-25-027146.txt ( ) — 4239KB
• allr-20250630.xsd (EX-101.SCH) — 39KB
• allr-20250630_cal.xml (EX-101.CAL) — 31KB
• allr-20250630_def.xml (EX-101.DEF) — 255KB
• allr-20250630_lab.xml (EX-101.LAB) — 248KB
• allr-20250630_pre.xml (EX-101.PRE) — 284KB
• allr20250630_10q_htm.xml (XML) — 538KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as at June 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) for the three and six months ended June 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) 4 Notes to Condensed Consolidated Financial Statements (Unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 12 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 18 Item 4.

Controls and Procedures

Controls and Procedures 18

— OTHER INFORMATION

PART II — OTHER INFORMATION 20 Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 22

Signatures

Signatures 23 i Table of Contents Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q (the "Quarterly Report") to the "Company," "Allarity," "we," "us," "our" and similar terms refer to Allarity Therapeutics, Inc., Allarity Therapeutics A/S (as predecessor) and its respective consolidated subsidiaries. On April 9, 2024, we effected a 1-for-20 reverse stock split of the shares of our common stock. On September 11, 2024, we effected a 1-for-30 reverse stock split of the shares of our common stock. All historical share and per share amounts reflected throughout this Quarterly Report have been adjusted to reflect the Reverse Stock Splits (as defined in this Quarterly Report). CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains statements we believe are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements are intended to enjoy the protection of the safe harbor for forward-looking statements provided by that act as well as protections afforded by other federal securities laws. Generally, words such as "achieve," "aim," "ambitions," "anticipate," "believe," "committed," "continue," "could," "designed," "estimate," "expect," "forecast," "future," "goals," "grow," "guidance," "intend," "likely," "may," "milestone," "objective," "on track," "opportunity," "outlook," "pending," "plan," "position," "possible," "potential," "predict," "progress," "roadmap," "seek," "should," "strive," "targets," "to be," "upcoming," "will," "would," and variations of such words and similar expressions identify forward-looking statements, which are not historical in nature. Forward-looking statements may appear throughout this Quarterly Report and other documents we file with the Securities and Exchange Commission (the "SEC"). Forward-looking statements involve risks and uncertainties that could cause actual results to differ materiall

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements . ALLARITY THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except for share and per share data*) June 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 17,801 $ 19,533 Receivables from ATM sales — 1,416 Other current assets 116 115 Prepaid expenses 1,357 507 Tax credit receivable 1,609 770 Total current assets 20,883 22,341 Non-current assets: Property, plant and equipment, net 322 309 Total assets $ 21,205 $ 22,650 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 4,605 $ 4,182 Accrued expenses and other current liabilities 2,977 5,232 Warrant derivative liability — 1 Income taxes payable 81 74 Convertible promissory notes and accrued interest, net of debt discount 1,375 1,350 Total current liabilities 9,038 10,839 Total liabilities 9,038 10,839 Commitments and contingencies (Note 9) Stockholders' equity Common stock, $ 0.0001 par value ( 250,000,000 shares authorized); 17,075,338 and 7,302,797 shares issued and 14,619,636 and 7,302,797 outstanding at June 30, 2025, and December 31, 2024, respectively 2 1 Additional paid-in capital 141,209 131,130 Accumulated other comprehensive loss ( 2,461 ) ( 354 ) Accumulated deficit ( 124,018 ) ( 118,966 ) Treasury stock, at cost; 2,455,702 shares ( 2,565 ) — Total stockholders' equity 12,167 11,811 Total liabilities and stockholders' equity $ 21,205 $ 22,650 * All common share data has been retroactively adjusted to effect reverse stock splits in 2024 (See Note 1). See accompanying notes to condensed consolidated financial statements. 1 Table of Contents ALLARITY THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (in thousands, except for share and per share data*) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Op

View Full Filing

View this 10-Q filing on SEC EDGAR